Home > Research > Publications & Outputs > Public finance of rotavirus vaccination in Indi...

Links

Text available via DOI:

View graph of relations

Public finance of rotavirus vaccination in India and Ethiopia: an extended cost-effectiveness analysis

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

Public finance of rotavirus vaccination in India and Ethiopia : an extended cost-effectiveness analysis. / Verguet, Stéphane; Murphy, Shane; Anderson, Benjamin et al.

In: Vaccine, Vol. 31, No. 42, 01.10.2013, p. 4902-4910.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

Verguet, S, Murphy, S, Anderson, B, Johansson, KA, Glass, R & Rheingans, R 2013, 'Public finance of rotavirus vaccination in India and Ethiopia: an extended cost-effectiveness analysis', Vaccine, vol. 31, no. 42, pp. 4902-4910. https://doi.org/10.1016/j.vaccine.2013.07.014

APA

Verguet, S., Murphy, S., Anderson, B., Johansson, K. A., Glass, R., & Rheingans, R. (2013). Public finance of rotavirus vaccination in India and Ethiopia: an extended cost-effectiveness analysis. Vaccine, 31(42), 4902-4910. https://doi.org/10.1016/j.vaccine.2013.07.014

Vancouver

Verguet S, Murphy S, Anderson B, Johansson KA, Glass R, Rheingans R. Public finance of rotavirus vaccination in India and Ethiopia: an extended cost-effectiveness analysis. Vaccine. 2013 Oct 1;31(42):4902-4910. doi: 10.1016/j.vaccine.2013.07.014

Author

Verguet, Stéphane ; Murphy, Shane ; Anderson, Benjamin et al. / Public finance of rotavirus vaccination in India and Ethiopia : an extended cost-effectiveness analysis. In: Vaccine. 2013 ; Vol. 31, No. 42. pp. 4902-4910.

Bibtex

@article{032272aabfb24b8c98f3b447f8c3a7b5,
title = "Public finance of rotavirus vaccination in India and Ethiopia: an extended cost-effectiveness analysis",
abstract = "BACKGROUND: An estimated 4% of global child deaths (approximately 300,000 deaths) were attributed to rotavirus in 2010. About a third of these deaths occurred in India and Ethiopia. Public finance of rotavirus vaccination in these two countries could substantially decrease child mortality and also reduce rotavirus-related hospitalizations, prevent health-related impoverishment and bring significant cost savings to households.METHODS: We use a methodology of 'extended cost-effectiveness analysis' (ECEA) to evaluate a hypothetical publicly financed program for rotavirus vaccination in India and Ethiopia. We measure program impact along four dimensions: 1) rotavirus deaths averted; 2) household expenditures averted; 3) financial risk protection afforded; 4) distributional consequences across the wealth strata of the country populations.RESULTS: In India and Ethiopia, the program would lead to a substantial decrease in rotavirus deaths, mainly among the poorer; it would reduce household expenditures across all income groups and it would effectively provide financial risk protection, mostly concentrated among the poorest. Potential indirect benefits of vaccination (herd immunity) would increase program benefits among all income groups, whereas potentially decreased vaccine efficacy among poorer households would reduce the equity benefits of the program.CONCLUSIONS: Our approach incorporates financial risk protection and distributional consequences into the systematic economic evaluation of vaccine policy, illustrated here with the case study of public finance for rotavirus vaccination. This enables selection of vaccine packages based on the quantitative inclusion of information on equity and on how much financial risk protection is being bought per dollar expenditure on vaccine policy, in addition to how much health is being bought.",
keywords = "Child, Preschool, Cost-Benefit Analysis, Ethiopia, Female, Health Policy, Hospitalization, Humans, India, Infant, Infant, Newborn, Male, Rotavirus Infections, Rotavirus Vaccines, Survival Analysis, Vaccination",
author = "St{\'e}phane Verguet and Shane Murphy and Benjamin Anderson and Johansson, {Kjell Arne} and Roger Glass and Richard Rheingans",
note = "Copyright {\textcopyright} 2013 Elsevier Ltd. All rights reserved.",
year = "2013",
month = oct,
day = "1",
doi = "10.1016/j.vaccine.2013.07.014",
language = "English",
volume = "31",
pages = "4902--4910",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "42",

}

RIS

TY - JOUR

T1 - Public finance of rotavirus vaccination in India and Ethiopia

T2 - an extended cost-effectiveness analysis

AU - Verguet, Stéphane

AU - Murphy, Shane

AU - Anderson, Benjamin

AU - Johansson, Kjell Arne

AU - Glass, Roger

AU - Rheingans, Richard

N1 - Copyright © 2013 Elsevier Ltd. All rights reserved.

PY - 2013/10/1

Y1 - 2013/10/1

N2 - BACKGROUND: An estimated 4% of global child deaths (approximately 300,000 deaths) were attributed to rotavirus in 2010. About a third of these deaths occurred in India and Ethiopia. Public finance of rotavirus vaccination in these two countries could substantially decrease child mortality and also reduce rotavirus-related hospitalizations, prevent health-related impoverishment and bring significant cost savings to households.METHODS: We use a methodology of 'extended cost-effectiveness analysis' (ECEA) to evaluate a hypothetical publicly financed program for rotavirus vaccination in India and Ethiopia. We measure program impact along four dimensions: 1) rotavirus deaths averted; 2) household expenditures averted; 3) financial risk protection afforded; 4) distributional consequences across the wealth strata of the country populations.RESULTS: In India and Ethiopia, the program would lead to a substantial decrease in rotavirus deaths, mainly among the poorer; it would reduce household expenditures across all income groups and it would effectively provide financial risk protection, mostly concentrated among the poorest. Potential indirect benefits of vaccination (herd immunity) would increase program benefits among all income groups, whereas potentially decreased vaccine efficacy among poorer households would reduce the equity benefits of the program.CONCLUSIONS: Our approach incorporates financial risk protection and distributional consequences into the systematic economic evaluation of vaccine policy, illustrated here with the case study of public finance for rotavirus vaccination. This enables selection of vaccine packages based on the quantitative inclusion of information on equity and on how much financial risk protection is being bought per dollar expenditure on vaccine policy, in addition to how much health is being bought.

AB - BACKGROUND: An estimated 4% of global child deaths (approximately 300,000 deaths) were attributed to rotavirus in 2010. About a third of these deaths occurred in India and Ethiopia. Public finance of rotavirus vaccination in these two countries could substantially decrease child mortality and also reduce rotavirus-related hospitalizations, prevent health-related impoverishment and bring significant cost savings to households.METHODS: We use a methodology of 'extended cost-effectiveness analysis' (ECEA) to evaluate a hypothetical publicly financed program for rotavirus vaccination in India and Ethiopia. We measure program impact along four dimensions: 1) rotavirus deaths averted; 2) household expenditures averted; 3) financial risk protection afforded; 4) distributional consequences across the wealth strata of the country populations.RESULTS: In India and Ethiopia, the program would lead to a substantial decrease in rotavirus deaths, mainly among the poorer; it would reduce household expenditures across all income groups and it would effectively provide financial risk protection, mostly concentrated among the poorest. Potential indirect benefits of vaccination (herd immunity) would increase program benefits among all income groups, whereas potentially decreased vaccine efficacy among poorer households would reduce the equity benefits of the program.CONCLUSIONS: Our approach incorporates financial risk protection and distributional consequences into the systematic economic evaluation of vaccine policy, illustrated here with the case study of public finance for rotavirus vaccination. This enables selection of vaccine packages based on the quantitative inclusion of information on equity and on how much financial risk protection is being bought per dollar expenditure on vaccine policy, in addition to how much health is being bought.

KW - Child, Preschool

KW - Cost-Benefit Analysis

KW - Ethiopia

KW - Female

KW - Health Policy

KW - Hospitalization

KW - Humans

KW - India

KW - Infant

KW - Infant, Newborn

KW - Male

KW - Rotavirus Infections

KW - Rotavirus Vaccines

KW - Survival Analysis

KW - Vaccination

U2 - 10.1016/j.vaccine.2013.07.014

DO - 10.1016/j.vaccine.2013.07.014

M3 - Journal article

C2 - 23871824

VL - 31

SP - 4902

EP - 4910

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 42

ER -